A Phase IIb study to evaluate AZD8965 in participants with IPF. - ARGiNAUT

Inclusion Criteria

• Inclusion Criteria:
• 1. Age ≥ 40 years
• 2. IPF diagnosis
• 3. Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care
• 4. FVC ≥ 45% predicted of normal
• 5. DLCO corrected for hemoglobin ≥ 25% predicted of normal
• Exclusion Criteria:
• 1. ILD other than IPF
• 2. The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan
• 3. Acute exacerbation of IPF
• 4. Lower respiratory tract infection requiring treatment
• 5. Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting
• 6. Heart failure
• 7. History of organ transplantation or is likely to receive lung transplantation